Lancet Neurology
An experimental drug shows promise in lowering the risk of Alzheimer’s dementia
Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain.
A new hope for patients with non-dystrophic myotonia
Mexiletine, a sodium channel blocker, was effective in treating non-dystrophic myotonia, making it the standard treatment.